Month: May 2020

(Selskabsmeddelelse 48/2020)De væsentligste ændringer i prospektet fremgår nedenfor:Prospektet er ændret i afsnittet vedr. aftaler om administration, porteføljerådgivning og formidling. Der foretages fra 1. juni fradrag i porteføljerådgivningshonoraret, såfremt der investeres i andre fonde, der rådgives af Sydbank. Honoraret for porteføljerådgivningen i Værdipapirfonden Sydinvest er i den forbindelse justeret op. Samlet har ændringen ført til fald i afdelingerne ÅOP, der ligeledes er ajourført i prospektet.Oplysninger om fondens nyvalgte bestyrelsesmedlem er tilføjet.Med venlig hilsenSyd Fund Management A/STlf. 74 37 33 00Vedhæftet filVSI Prospekt 2020.05.26_Final

LAS VEGAS, May 29, 2020 (GLOBE NEWSWIRE) — Live Ventures Incorporated (Nasdaq: LIVE), a diversified holding company, today announced that Jon Isaac, its President and Chief Executive Officer, purchased 28,672 shares of the company’s common stock for a total purchase price of approximately $263,000. The shares were purchased in the open market on May 28, 2020. Mr. Isaac filed a Form 4 which is available at the website of U.S. Securities and Exchange Commission at http://www.sec.gov.About Live VenturesLive Ventures Incorporated, originally incorporated in 1968, is a diversified holding company with several wholly owned subsidiaries and a strategic focus on acquiring profitable companies that have demonstrated a strong history of earnings power. Through its subsidiary Marquis Industries, the company manufactures and sells residential...

TORONTO, May 29, 2020 (GLOBE NEWSWIRE) — CF Energy Corp. (TSX-V: CFY) (“CF Energy” or the “Company”, together with its subsidiaries, the “Group”), an energy provider in the People’s Republic of China (the ”PRC” or “China”), announces that the Company has filed its unaudited condensed interim consolidated financial results for the three-month period ended March 31, 2020 (“Q1 2020”).Results for the Three-Month Period Ended March 31, 2020Since the outbreak of COVID-19 pandemic in late January 2020, the Group experienced a significant drop in revenue across all our business segments in Q1 2020. The economic damage caused by the COVID-19 pandemic is largely driven by a fall in gas demand due to the imposition of government protective and containment measures such as quarantine and travel restrictions and temporary cessation of businesses...

Investeringsforeningen PFA Invest er igen i stand til at beregne indre værdier, og der anmodes om ophævelse af suspension for nedenstående afdelinger i Investeringsforeningen PFA InvestEventuel henvendelse vedrørende denne meddelelse kan rettes til Stine Bernt Simonsen på sbs@pfa.dk eller på telefon 39 17 60 87.Med venlig hilsenPFA Asset Management A/S

ROCHESTER, Mich., May 29, 2020 (GLOBE NEWSWIRE) — OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, payers and providers, has been invited to present in William Blair & Company’s 40th Annual Growth Stock Conference being held June 9-11, 2020.OptimizeRx CEO William Febbo is scheduled to present on June 10, 2020, at 9:20 a.m. Central time, as well as participate in virtual one-on-one meetings on the same day and June 11.He will discuss a number of topics, including how OptimizeRx’s record Q1 results demonstrated an acceleration in platform adoption and the further transformation of the company’s revenue model into SaaS-based enterprise-level deployments. He will also discuss how COVID-19 has made OptimizeRx’s nationwide digital connectivity at the point-of-care even more...

Undifferentiated Pleomorphic Sarcoma is the Major Sarcoma Subtype to be Enrolled inTRACON’s Pivotal ENVASARC Trial of Envafolimab as a Single Agent and in Combination with YervoyPivotal ENVASARC Trial to Start in the Second Half of 2020SAN DIEGO, May 29, 2020 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today highlighted data from poster #11511 at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, entitled,  “Multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic...

The addition of ublituximab to ibrutinib significantly improved PFS, ORR, CR rate, and increased rates of uMRD compared with ibrutinib monotherapyNEW YORK, May 29, 2020 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the final results from the GENUINE Phase 3 study evaluating the combination of ublituximab, the Company’s novel glycoengineered anti-CD20 monoclonal antibody, plus ibrutinib compared to ibrutinib alone in patients with previously treated high-risk chronic lymphocytic leukemia (CLL) at the 56th American Society of Clinical Oncology (ASCO) annual meeting.Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, “We are extremely pleased with the final results of the GENUINE Phase 3 trial presented today. Not only is this the first randomized trial to show a PFS benefit...

SAN DIEGO, May 29, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today at the ASCO Annual Meeting presented a preclinical update for its novel, clinical-stage, selective RET-inhibitor drug candidate, TPX-0046.In the updated preclinical studies comparing proxy molecules for approved and investigational RET inhibitors, TPX-0046 demonstrated potent in vitro and in vivo activity against a range of RET alterations, including greater potency against solvent-front mutations, G810S, G810R, G810C and G810N.A phase 1/2 trial of TPX-0046 in RET TKI-naïve and -pretreated patients is ongoing.“TPX-0046 was designed as a potent RET inhibitor with the potential to address TKI-naïve and RET inhibitor-resistant RET-dependent...

Phase 3 data presented in oral presentation during the ASCO20 Virtual Scientific Program, with simultaneous publication in the New England Journal of MedicinePresentation expands on previous results demonstrating superiority of relugolix to leuprolide acetate, with additional data on testosterone suppression and recovery, prostate-specific antigen (PSA) response, and cardiovascular safety Relugolix treatment showed a 54% lower risk of major adverse cardiovascular events compared to leuprolide acetateConference call and webcast to be held Monday, June 1 at 8:30 a.m. EDT / 5:30 a.m. PDTBASEL, Switzerland, May 29, 2020 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced additional results from its Phase 3 HERO study of once-daily, oral relugolix (120...

Mondelēz International contributed to JDE Peet’s successful listing on Euronext AmsterdamCompany will retain two board seats at the global coffee and tea company on listingCHICAGO, May 29, 2020 (GLOBE NEWSWIRE) — Mondelēz International, Inc. (NASDAQ: MDLZ) today announced its participation in JDE Peet’s admission to listing and trading of its ordinary shares on Euronext Amsterdam (Euronext Amsterdam: JDEP) and confirmed that it will be selling a portion of its stake in the coffee and tea company as part of the secondary component of JDE Peet’s offering. The offer price was set at €31.50 per share.After settlement and depending on exercise of the over-allotment option, Mondelēz International’s stake in JDE Peet’s will be between 22.9 percent and 23.4 percent. Mondelēz International will retain two seats on the board of JDE Peet’s,...